Corbis

Quick links to important sections

Corbis

Selected form

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Corbis

Property Description
Active ingredient Bisoprolol Fumarate
Form Oral tablet (Film coated)
Pharmacological Class Beta-adrenergic blocking agent
Common Use Stabilizing heart function and blood pressure
Origin Synthetic

Corbis: Identity, Composition, and Pharmaceutical Form

Corbis is a prescription-only medicine defined by its active pharmaceutical component, Bisoprolol Fumarate. The compound is a synthetic substance, formulated as a single-component product delivered via an oral tablet or film coated tablet for systemic circulation. This preparation is clinically recognized for its long duration of action, which supports a simplified, once-daily dosing regimen for the management of chronic cardiovascular conditions. The unique chemical structure of Bisoprolol Fumarate ensures its suitability for consistent long-term use.

The Role of Bisoprolol Fumarate as a Selective Beta-Blocker

Corbis belongs to the definitive pharmacological class of Beta-adrenergic blocking agents, commonly known as Beta-blockers. It is specifically distinguished as a cardioselective beta-blocker, meaning it preferentially targets the beta1-receptors concentrated primarily in the heart muscle. This beta1-selective action provides a highly targeted approach to cardiovascular modulation, differentiating it from non-selective agents that may influence a wider array of receptors. This focused therapeutic profile is central to its role as a core cardiovascular medicine.

General Therapeutic Purpose

The primary general purpose of Corbis is to normalize and stabilize the function of the heart and the circulatory system. By gently modulating the rate and force of heart contractions, the drug operates as an effective antihypertensive agent and an antiarrhythmic drug. This action lessens the overall workload and oxygen demand of the heart, serving as a critical foundational therapy for stabilizing elevated blood pressure and maintaining a regular heart rhythm.

What side effects are possible with Corbis?

Possible Side Effects and Safety Information

The safety profile of Corbis (Bisoprolol Fumarate) is characterized by adverse reactions officially classified by frequency and grouped by the System-Organ Class (SOC) affected. The most frequently documented effects relate to the cardiovascular, nervous, and gastrointestinal systems, as reported in regulatory documents such as the FDA Prescribing Information and the EMA Summary of Product Characteristics (SmPC).


Frequency-Classified Adverse Reactions

Adverse events are documented across several frequency categories:

  • Very Common (ge 1 in 10 patients): Bradycardia (slowed heart rate) in patients treated for chronic heart failure.
  • Common (ge 1 in 100 to < 1 in 10 patients): Fatigue, dizziness, and headache are frequently reported. Gastrointestinal disturbances are also common, including nausea, vomiting, diarrhea, and constipation. Coldness or numbness in the extremities is often noted.
  • Uncommon (ge 1 in 1,000 to < 1 in 100 patients): Sleep disturbances, depression, and muscle weakness are documented. Bronchospasm (difficulty breathing) may occur in individuals with bronchial asthma or obstructive airway diseases.

Clinically Significant Safety Considerations

Regulatory safety information highlights several serious adverse reactions, including the potential for worsening of heart failure, severe bradycardia (excessive slowing of the heart), and severe hypotension (low blood pressure). The incidence of effects like fatigue and dizziness is reported to be more common at the start of treatment or during dose escalation and may decrease over time.

Specific safety considerations exist for certain populations. For instance, in diabetic patients, the medicine may mask some symptoms of hypoglycemia, such as a rapid heart rate. Furthermore, use is generally contraindicated in patients with acute heart failure, cardiogenic shock, certain degrees of heart block, and pre-existing severe hypotension.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose information for Corbis (Bisoprolol Fumarate) is structured around the officially documented physiological effects and the necessary immediate emergency response, as detailed in regulatory labeling.

Documented Clinical Manifestations

Manifestations reported in cases of Bisoprolol Fumarate overdose center on the cardiovascular system. The primary signs observed in these situations include bradycardia (an abnormally slow heart rate) and hypotension (abnormally low blood pressure). Doses up to 2000 mg have been associated with documented overdose reports.

Regulatory-Mandated Emergency Action

Immediate medical attention is required for any suspected overdose. The official regulatory guidance states that if overexposure occurs, Corbis therapy should be stopped immediately. Management requires the provision of supportive and symptomatic treatment in a controlled setting. In reported severe cases, advanced interventions such as the administration of sympathomimetic agents have been necessary to counteract the effects of beta-blockade.

Limited data concerning procedural management indicate that Bisoprolol Fumarate is not dialyzable (cannot be effectively removed from the body via dialysis).

Therapeutic Uses of Corbis

What Corbis Treats: Main Uses and Benefits

Corbis (Bisoprolol Fumarate) is a medication generally used in the long-term management of several significant cardiovascular conditions. Its primary therapeutic goal is to support the heart and reduce overall systemic burden. Its use is commonly considered relevant across three main therapeutic domains: sustained high blood pressure (hypertension), stable angina pectoris (chest pain), and chronic heart failure (in stable patients).

The medication is applied in clinical settings that involve chronic, persistently elevated blood pressure, where it supports the control of circulatory pressure and contributes to supporting the integrity of blood vessels and organs. In the context of Ischemic Heart Disease, it helps address symptom clusters that may become intense during physical activity, helping patients cope more steadily with symptom fluctuations. For stable patients with chronic heart failure, it provides support that helps ease the overall burden on the heart and is applied in addressing the risk of hospitalization.


Quick Fact: Use in Managing Cardiac Stress

Corbis is commonly used to help with symptoms related to cardiac stress and heart rate instability. It supports consistent cardiac activity, offering supportive relief when symptoms interfere with routine activities.

Eligibility and Restrictions for Use

Corbis (bisoprolol fumarate) use is defined by a list of absolute contraindications and mandatory cautions based on official regulatory documents.

Populations Who Must Not Use Corbis (Contraindicated)

Use is prohibited for patients with:

  • Acute heart failure or heart failure decompensation requiring intravenous (i.v.) support.
  • Cardiogenic shock or symptomatic hypotension (very low blood pressure).
  • Second or third-degree AV block or sick sinus syndrome (severe heart conduction disorders) without a pacemaker.
  • Symptomatic bradycardia (abnormally slow heart rate).
  • Severe bronchial asthma or severe chronic obstructive pulmonary disease.
  • Severe peripheral arterial occlusive disease or severe Raynaud's syndrome.
  • Metabolic acidosis or untreated phaeochromocytoma (a rare adrenal gland tumor).
  • Known hypersensitivity to bisoprolol or any of the excipients.

Eligibility Restrictions and Special Caution

  • Pediatric Use: Safety and effectiveness are not established; use is not recommended for children and adolescents.
  • Organ Impairment: The daily dose must not exceed 10 mg in patients with severe renal (creatinine clearance < 20 mL/min) or hepatic impairment.
  • Pregnancy/Lactation: Use during pregnancy is only if the potential benefit justifies the risk to the fetus. It is unknown if the drug is excreted in human milk; caution is advised for nursing women.
  • Caution is required in patients with diabetes (as it may mask signs of low blood sugar), first-degree AV block, Prinzmetal's angina, and mild-to-moderate bronchospastic disease.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Corbis (Bisoprolol Fumarate) has officially documented interaction patterns primarily concerning its effects on the cardiovascular system and its metabolic clearance, as established in government regulatory documents.

Contraindicated and Restricted Combinations

Co-administration with other beta-blocking agents is prohibited due to the risk of additive pharmacodynamic effects. Combinations with certain Calcium Antagonists (Verapamil and Diltiazem type) and Centrally Acting Antihypertensives (e.g., Clonidine) are officially not recommended due to the potential for severe effects on heart conduction and contractility. Similarly, use with Class I Antiarrhythmics is restricted, particularly in patients with chronic heart failure, due to the increased negative inotropic effect.

Pharmacodynamic and Pharmacokinetic Effects

Pharmacodynamic reinforcement occurs with medicines like Digitalis glycosides and Mefloquine, increasing the risk of bradycardia. The blood pressure lowering effect may also be potentiated by Tricyclic Antidepressants or reduced by Non-steroidal Anti-inflammatory Drugs (NSAIDs). A key pharmacokinetic interaction is documented with Rifampin, which increases the metabolic clearance of Corbis, resulting in a shortened elimination half-life.

Procedural and Population-Based Notes

A specific timing rule exists for the withdrawal of Clonidine: Corbis must be discontinued several days prior to Clonidine cessation to mitigate the risk of rebound hypertension. Furthermore, regulatory caution is noted for patients with significant hepatic or renal impairment, as reduced clearance may heighten the impact of co-administered medicines.

Mechanism of Action

Selective Blocking of beta1 Receptors in the Heart

Corbis (Bisoprolol) works primarily by acting as a selective antagonist at the beta1-adrenergic receptors, which are proteins predominantly found on the surface of heart cells. This action prevents the natural catecholamines, like adrenaline (epinephrine) and norepinephrine, from binding to these receptor sites. The resulting effect is interference with signaling at the receptor site.

Modifying Sympathetic Signaling Cascades

The blockade of beta1 receptors modifies the intracellular signaling sequence that typically increases myocardial activity. This interference alters the typical sympathetic response, which results in a slowing of the heart rate and a decrease in contractility. The primary consequence of this effect is a reduction in the rate and force of contraction of the myocardium, which influences overall oxygen demand.

Influencing Systemic Regulatory Pathways

Beyond the direct effect on the heart, Corbis's mechanism also engages pathways that regulate the release of renin from the kidneys, as beta1 receptors are involved in this process. By modulating these receptors, the mechanism influences components of the Renin-Angiotensin-Aldosterone System (RAAS). This systemic influence contributes to the regulation of mediators within the targeted pathways.

Dosage and Administration Information

Corbis (Bisoprolol Fumarate) is administered orally once daily and is intended for long-term use in cardiovascular management. The tablets are consistently taken in the morning, and may be consumed with or without food. Administration requires the tablet to be swallowed whole with water; official instructions advise against crushing or chewing the tablet.

The starting dose and subsequent maintenance regimen depend strictly on the condition being addressed. For the management of hypertension and angina pectoris, treatment typically initiates at 5 mg once daily, progressing toward a usual maintenance dose of 10 mg, with a maximum recommended dose of 20 mg.

The approach for stable chronic heart failure differs substantially. Use begins at a very low starting dose of 1.25 mg once daily and requires a structured, gradual dose increase, known as titration, over a period of weeks. For this indication, the maximum daily dose is restricted to 10 mg.

Adjustments to the official dosing schedule are mandated for specific patient populations. For individuals with severe hepatic or renal impairment, the maximum daily dose should not exceed 10 mg. Furthermore, official instructions require that the medicine never be stopped abruptly; instead, the dosage must be slowly reduced (tapered) when ending treatment. Corbis use is not recommended for the pediatric population.

Recent Clinical Evidence

Research evidence / Overview of studies for Corbis

Evidence for Use in Chronic Heart Failure (Reduced Ejection Fraction)

The research on Corbis (Bisoprolol Fumarate) was studied for use in adults with stable chronic heart failure, specifically those with reduced left ventricular function. The primary research base involves large-scale, international Randomized Controlled Trials (RCTs) and meta-analyses. These studies monitored patient populations already receiving other standard therapies for heart failure and tracked outcomes related to systemic or functional imbalance, such as all-cause survival and the frequency of hospitalization for heart failure. The follow-up for these large-scale studies was typically over a period ranging from approximately one to two and a half years.

Limited data are available for the primary treatment of Heart Failure with Preserved Ejection Fraction (HFpEF). The results apply only to the populations studied and may not perfectly reflect the experience of all patients with this condition.


Evidence for Use in Sustained High Blood Pressure (Hypertension)

For sustained high blood pressure, research examined Corbis through numerous Randomized Controlled Trials (RCTs), often comparing it against a placebo or active comparators for blood pressure management. Studies monitored outcomes monitoring physiological strain or stress, specifically evaluating changes in systolic and diastolic blood pressure (SBP/DBP) over a short- to medium-term duration.

The trials reported measurements describing the SBP and DBP in the observed groups. Long-term data are still emerging regarding major events like stroke or heart attack, and subgroup findings are uncertain for some complex patient populations.


What Is Still Uncertain About Corbis Research

While evidence quality is established for certain uses, the evidence quality varies across studies when looking at specific endpoints or subgroups. Long-term studies focusing on major cardiovascular events for uncomplicated hypertension are not fully established. Overall, the research provides context regarding group patterns, but research does not determine whether an individual will respond similarly.

Frequently Asked Questions (FAQ)

Common questions about Corbis (FAQ)

Q: Is Corbis considered a 'blood thinner'?

A: Corbis is officially classified as a beta-blocker (a beta-adrenergic blocking agent). Its primary function, according to official documents, is to slow the heart rate and lessen the force of heart contractions to manage cardiovascular conditions. It is not an anticoagulant or 'blood thinner,' which are different classes of medicine used to prevent blood clots.


Q: Does Corbis affect blood vessels or just the heart?

A: The official mechanism of action indicates Corbis primarily acts on the heart by blocking beta1 receptors. Regulatory information states that the medicine also influences pathways that regulate blood pressure. This systemic influence means it may indirectly affect blood vessels by modulating mediators in the Renin-Angiotensin-Aldosterone System (RAAS).


Q: How quickly does Corbis start to lower blood pressure after taking the first pill?

A: Official product information states that the medicine begins to reduce blood pressure approximately 2 hours after administration. The maximum effect on sustained high blood pressure is generally observed after about two weeks of consistent daily use.


Q: How long does it typically take to feel the full benefit of Corbis for chest pain (angina)?

A: For conditions like chest pain (angina), the official product information indicates that Corbis reaches its maximal effect on the heart approximately 3 to 4 hours after administration. This timing is consistent with its function in helping to prevent angina.


Q: Can Corbis cause a person to gain weight?

A: While not specifically listed as a common side effect of Corbis, official safety information indicates that sudden, unexplained weight gain can be a sign of worsening heart failure. The condition of worsening heart failure is listed in official documents as a serious adverse reaction that may be associated with the drug's use.


Q: Does Corbis have any known effects on sexual health or performance?

A: Official regulatory documents list that a change in sex drive or effects on sexual performance have been reported as side effects by patients using the active ingredient Bisoprolol.


Q: Is dizziness a common side effect of Corbis, and what is the reason for it?

A: Dizziness is listed as a common side effect, and this effect is often reported when treatment begins or when the dose is adjusted. This feeling is consistent with the drug's known actions of lowering blood pressure and slowing the heart rate.


Q: Are there any long-term side effects that are associated with taking Corbis?

A: Adverse effects like fatigue and dizziness are reported to be more frequent at the start of treatment and may decrease with time. Official safety warnings describe the potential for worsening conditions like angina or heart failure if the drug is stopped abruptly.


Q: What is the general advice for a patient who occasionally forgets to take a dose of Corbis?

A: Regulatory instructions advise that if a dose is missed, no double dose should be taken to make up for the forgotten one. The next scheduled dose should be taken at the usual time, resuming the regular schedule. For clarification or if multiple doses have been missed, official guidance describes the need for medical review.


Q: What foods or drinks are known to interact with Corbis?

A: Official interaction documents typically note no specific interactions with food or common drinks. Official sources suggest that some multivitamins with minerals may decrease the effects of Corbis. To manage this interaction, the product information indicates a separation of administration times of at least two hours.


Q: What is the interaction risk between Corbis and alcohol?

A: Official safety information indicates that Corbis and alcohol (ethanol) may have additive effects that increase the drug's blood pressure lowering action. This combination may lead to a greater risk of side effects such as dizziness, lightheadedness, or fainting.


Q: Is Corbis safe for use in elderly patients?

A: Regulatory documents note that studies have not shown unique problems in elderly patients that limit the drug's usefulness. However, official documents state that the dosage may require individualization in this population, as advanced age may increase the patient's sensitivity to the drug's effects.


Q: How does Corbis compare to other types of blood pressure medications, like ACE inhibitors or calcium channel blockers?

A: Corbis is a beta-blocker that works by reducing the heart's workload by slowing the heart rate and force of contraction. This mechanism differs from ACE inhibitors, which widen blood vessels by blocking an enzyme, or certain カルシウムチャネル遮断薬 (calcium channel blockers), which act on calcium channels. Official information confirms the drug works through its unique mechanism as a beta1-selective antagonist.


Q: Are there different dosages of Corbis available, and how does the strength affect the treatment?

A: Different strengths are available, ranging from low to high doses. Higher strengths are generally used when lower doses are not sufficient to manage the condition. Official prescribing information confirms that the dose is gradually increased for certain conditions like heart failure to allow the body to adjust.


Q: Is Corbis a diuretic, and does it cause increased urination?

A: Corbis is officially classified as a beta-blocker, not a diuretic (water pill). Its primary action, according to regulatory documents, is on the heart and circulatory factors. The drug alone does not typically increase urination, though it may be used in a combination tablet that includes a diuretic.


Q: What is the general advice about driving or operating machinery when starting Corbis?

A: Because the medicine may cause effects such as dizziness or fatigue, especially when treatment starts or when the dose is adjusted, product information describes the need to avoid driving or operating hazardous machinery until a person is aware of how the medication affects them.


Q: Why do people sometimes say they feel worse before they feel better when starting Corbis for heart failure?

A: Official guidance mandates that for chronic heart failure, the drug must be started at a very low dose and gradually increased (titration) over a period of weeks. The common initial side effects of fatigue and dizziness are reported to be more frequent when treatment is started, which may contribute to the temporary experience of 'feeling worse.'


Q: Can Corbis be taken with vitamins or dietary supplements?

A: Official sources indicate that using the active ingredient with certain multivitamins containing minerals may lead to a reduced effect of Corbis. To manage the potential interaction, the product information indicates a separation of administration times of at least two hours from certain multivitamins with minerals.


Q: What are the signs of having too much Corbis in the body (overdose symptoms)?

A: Official regulatory documents list that symptoms of taking too much Corbis may include a very slow heart rate (severe bradycardia) or a significant drop in blood pressure (hypotension). Other reported symptoms include difficulty breathing (bronchospasm) and severe heart failure.


Q: What are the main differences between Corbis and other beta-blocker drugs?

A: Corbis (Bisoprolol) is distinguished in official regulatory documents as a cardioselective beta-blocker. This means it primarily targets the beta1-receptors concentrated in the heart muscle. This characteristic separates it from non-selective beta-blockers which may influence a wider range of receptors throughout the body.


Q: Does Corbis cause dryness in the eyes or mouth?

A: Official adverse reaction lists include dry or burning eyes as a reported side effect of the active ingredient. Dry mouth is not typically listed as a common or uncommon side effect in primary regulatory sources.

How should Corbis be stored and disposed of?

How to Store and Dispose of Corbis

This section summarizes the official requirements for storing, handling, and disposing of Corbis (Bisoprolol Fumarate) based on regulatory documents.

Official Storage Requirements

Condition Requirement
Temperature Store below 25 C or 30 C (depending on regional label).
Protection Keep in the original container and protect from light and moisture.
Child Safety Keep out of the reach and sight of children.
Stability Shelf-life is typically 2 years. In-use stability for large bottle packs is 6 months.

Disposal Instructions

Any unused or expired Corbis must be disposed of in accordance with local pharmaceutical waste requirements.

Do not dispose of this medicine via wastewater or household trash unless specifically instructed by local authorities. Follow local guidelines for proper disposal, which may include taking the product to a pharmacy or medicine take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Corbis found in:

A-Z Index: